查詢結果分析
來源資料
相關文獻
- 晚期鼻咽癌同步化學放射治療與單獨放射治療臨床結果之比較--隨機分組試驗初步報告
- Radiotherapy Versus Combined Radiotherapy and Chemotherapy for T[feb2]Nasopharyngeal Carcinoma
- Hemoglobin Level during Chemoradiation Therapy Predicts Treatment Outcome in Nasopharyngeal Cancer
- Preliminary Results of Intensity-Modulated Radiotherapy in the Treatment of Nasopharyngeal Carcinoma
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx
- Definitive Radiotherapy with Or Without Chemotherapy for Resectable Head and Neck Cancer
- 鼻咽癌病人放射線黏膜炎之抑制--比較Salcoat與Dexaltin之隨機取樣試驗
頁籤選單縮合
題名 | 晚期鼻咽癌同步化學放射治療與單獨放射治療臨床結果之比較--隨機分組試驗初步報告=Comparison of Concomitant Chemoradiotherapy vs. Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma-Preliminary Report of a Randomized Trial |
---|---|
作者 | 林進清; 詹建勝; 許振益; 江榮山; 陳寶蓮; | 書刊名 | 放射治療與腫瘤學 |
卷期 | 6:3 1999.09[民88.09] |
頁次 | 頁187-196 |
分類號 | 416.879 |
關鍵詞 | 鼻咽癌; 放射治療; 化學治療; Nasopharyngeal carcinoma; Radiotherapy; Chemotherapy; |
語文 | 中文(Chinese) |
中文摘要 | 目的:比較同步化學放射治療與單獨放射治療,對晚期鼻咽癌療效及副作用之差異。 材料與方法:自1993年12月起,選擇經病理切片証實之晚期(1992年AJCC第三、四期)鼻咽 癌病人,年齡小於80歲,一般狀況良好,肝、腎及骨髓功能正常,未曾接受任何抗癌治療, 且沒有遠處轉移者,經病人同意後,隨機分二組治療,實驗組接受同步化學放射治療,對照組 接受單獨放射治療,放療總劑量為70-75 Gy/6-8週,同步化學治療採用cisplatin和5-FU, 在放療中第一和第五週同時給予二次化療。 結果:本研究分析120例晚期鼻咽癌病人,治療後最少已追□三年之結果,兩組各有60例, 病人特徵分佈兩組類似。在治療結束後二個月評估,兩組腫瘤反應沒有顯著差異;治療引起的 急性反應,除了白血球降低程度同步化學放射治療組較嚴重,其它副作用兩組沒有差異;存活 曲線分析發現,兩組之四年鼻咽部控制率、頸部控制率、和遠處轉移控制率分別為91.6% vs. 75.5%、93.7% vs. 88.8%、和73.4% vs. 70.7%,其中鼻咽部控制率,同步化學放射治療組 優於單獨放射治療組,幾乎達統計學差異(P=0.0753);兩組之四年總存活率和四年疾病無惡化 存活率,分別為68.6% vs. 53.5%和70.1% vs. 55.1%,同步化學放射治療組較好,但未達統 計學差異(P>0.05);兩組治療失敗都以遠處轉移居多。 結論:同步化學放射治療對晚期鼻咽癌比單獨放射治療之局部控制率好,副作用兩組類似,遠 處轉移是治療失敗的主要原因,放療前後追加足量有效之輔助性化學治療,以減少遠處轉移 發生,提高存活率,值得進一步研究。 |
英文摘要 | Purpose: To compare the effect and toxicity of concomitant chemoradiotherapy (CRT) and radiotherapy alone (RT) for advanced nasopharyngeal carcinoma (NPC). Materials and Methods: A phase III randomized trial was conducted since December 1993. Patients with previously untreated and pathologic diagnosis of NPC were eligible. These included 1) 1992 AJCC stage III/IV; 2) Karnofsky scale > 50%; 3) age < 80 years old; 4) normal liver, renal, and bone marrow function; 5) no distant metastasis: 6) obtaining informed consent. Radiotherapy was administered in both arms with total dose of 70-75 Gy/6-8 weeks using a similar fractionation and technique. The concomitant chemotherapy consisted of cisplatin + 5-FU continuous intravenous infusion during the first and fifth weeks of radiotherapy. Results: This preliminary analysis included 120 patients who were followed at least 3 years after treatment. It was compatible between the two groups in patients' characteristics. Tumor response were evaluated 2 months after treatment which showed no difference between CRT and RT. Acute toxicity was similar except for leucopenia which occurred more frequently and more severe in CRT arm. But most patients in both arms tolerated the treatment course smoothly. The 4-year primary disease-free, regional disease-free and distant metastasis disease-free survival rates were 91.6% vs. 75.5%, 93.7% vs. 88.8%, and 73.4% vs. 70.7%, respectively in CRT and RT groups. CRT has better local control than RT with a borderline significant difference (P=0.0753). The 4-year overall survival and progression-free survival rates were 68.6% vs. 53.5% and 70.1% vs. 55.1% respectively, favored CRT groups but the difference was not statistically significant. Distant metastasis was the predominant site of failure in both arms. Conclusion: Concomitant chemoradiotherapy is better than radiotherapy alone in local control rate for advanced NPC. However, most patients failed at distant site(s). Adequate and effective neoadjuvant or adjuvant chemotherapy before or after radiotherapy to eradicate subclinical micrometastasis should be further consideration. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。